LENZ — LENZ Therapeutics, Inc.

LENZ Therapeutics Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: Closed Q4 2025 with approximately $292.3 million in cash and equivalents, remaining debt-free.
• Net Product Revenues: Reported $1.6 million in net product revenues from the launch of VIZZ, with over 20,000 monthly paid and filled prescriptions.
• Operating Expenses: Total operating expenses were approximately $40 million, with $39.6 million attributed to SG&A, primarily driven by the establishment of the sales force and the launch of a direct-to-consumer (DTC) campaign.
• Net Loss: Reported a net loss of $35.9 million, translating to a loss per share of $1.16.

2. Strategic Updates and Business Highlights

• Product Launch: VIZZ, a presbyopia treatment, has been launched for about five months, with promising early adoption signals. Over 45,000 boxes sold and prescribed by more than 10,000 eye care professionals (ECPs).
• Market Positioning: VIZZ is positioned as the only once-daily eye drop for presbyopia, targeting a market of approximately 128 million affected individuals in the U.S.
• Sales Force Expansion: Increased field representatives from 88 to 117 to enhance engagement with ECPs and accelerate adoption.
• Consumer Campaign: DTC campaign featuring Sarah Jessica Parker launched in January, leading to a 5x increase in website traffic and positive engagement metrics.

3. Forward Guidance and Outlook

• Patient Adoption: Expectation of gradual growth in new patient starts as both physician engagement and consumer awareness build over time, with a more significant impact anticipated in the second half of 2026.
• Refill Rates: Early signals indicate encouraging refill behavior, with patients transitioning from 1-month to 3-month prescriptions.
• Sales Strategy: Continued focus on optimizing marketing strategies and expanding the sales force to increase prescription volume.

4. Bad News, Challenges, or Points of Concern

• Gradual Adoption: The ramp-up in new patient starts is slower than initially hoped, typical for new treatment categories. The company is addressing this through enhanced physician education and marketing efforts.
• Market Competition: While VIZZ is unique, there are other entrants in the presbyopia market, necessitating ongoing efforts to differentiate and educate ECPs and patients.
• Cash Burn: A net cash burn of approximately $32 million in Q4 raises concerns about sustainability if revenues do not increase significantly in the near term.

5. Notable Q&A Insights

• Sampling Strategy: Over 90% of new patients have received samples, which is crucial for driving adoption. The conversion from samples to prescriptions is not yet tracked but is expected to improve as awareness grows.
• Prescriber Behavior: Top prescribers are writing 40% more scripts than comparable prescribers of VUITY, indicating strong physician enthusiasm for VIZZ.
• Market Education: There is a need to correct misconceptions that VIZZ is only for early presbyopes; efforts are underway to educate ECPs about its broader applicability.
• DTC Effectiveness: Early indicators from the DTC campaign show positive engagement, but it typically takes two quarters to see a significant impact on prescription trends.

Overall, LENZ Therapeutics is in the early stages of establishing VIZZ in the market, with a solid financial foundation and strategic initiatives aimed at driving growth, despite facing challenges typical of new product launches.